申请人:H. Lundbeck A/S
公开号:US05002948A1
公开(公告)日:1991-03-26
The present invention relates to novel piperazinylbutylindoles, -indazoles, the corresponding 2,3-dihydro derivatives and 2-indolones which have been found to have central serotonin activity with preference for the serotonin 5-HT.sub.lA receptor. Compared to the anxiolytic drug buspirone, and other clinically investigated compounds such as ipsapirone and gepirone, most of the present compounds have lower efficacy at the 5-HT.sub.lA receptor which implies less side effects related to activation of the receptors. The invention also includes acid addition salts, methods of preparation, pharmacetical compositions and method of treating CNS disorders occuring in anxiety, depression, aggression and in alcohol abuse, or in states of disease related to the cardiovascular, gastrointestinal and renal systems, by administering the aforementioned derivatives. Separation and use of the stereo isomers of the 2,3-dihydro derivatives and 2-indolones are also part of this invention.
本发明涉及新型哌嗪基丁基吲哚、吲唑、相应的2,3-二氢衍生物和2-吲哚酮,这些化合物已被发现具有中枢血清素活性,并对血清素5-HT.sub.lA受体具有优先选择性。与抗焦虑药丁螺环酮、以及其他临床研究化合物如伊普西龙和格匹龙相比,大多数本发明化合物在5-HT.sub.lA受体上的效力较低,这意味着与激活受体相关的副作用较少。本发明还包括酸盐加成物、制备方法、药物组成物以及通过给予上述衍生物治疗出现在焦虑、抑郁、攻击性和酗酒中的中枢神经系统疾病,或与心血管、胃肠和肾脏系统相关的疾病状态的方法。分离和使用2,3-二氢衍生物和2-吲哚酮的立体异构体也是本发明的一部分。